The Division of Drug Information (DDI) is CDER's focal point for public inquiries. We serve the public by providing information on human drug products and drug product regulation by FDA.
On June 21, 2013, the U.S. Food and Drug Administration expanded the approved use of the antibiotic Vibativ (telavancin) to treat patients with hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) caused by Staphylococcus aureus. Vibativ should be used for the treatment of HABP/VABP only when alternative treatments are not suitable.
Bacterial pneumonia is a lung infection that can be caused by many different types of bacteria. Vibativ is approved only to treat S. aureus, not other bacteria that cause pneumonia. HABP/VABP, also known as nosocomial pneumonia, is a particularly serious lung infection because patients in the hospital and especially those on ventilators are often already very sick and usually cannot fight the infection.
For more please visit: Vibativ
.png)
No hay comentarios:
Publicar un comentario